New drug VSA012 takes first step in human safety trial
NCT ID NCT06766929
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage study tests VSA012, a drug that targets the complement system (part of the immune system), in 40 healthy volunteers. The main goal is to check safety and how the drug moves through the body after a single dose. It is a first step before testing in patients with complement-driven diseases like PNH.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- VSA012
- What this could lead to
- If successful, this could pave the way for treating diseases like PNH where the complement system is overactive.
- What could go wrong
- This is a very early, small study in healthy people, not patients. It only tests safety and dosing, not whether the drug works for any disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Peking University Third Hospital
Beijing, Beijing Municipality, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A 10-second sprint may reveal who gains the most muscle from weight training
- Can a needle and a zap boost athletic performance? a trial puts five nerve-stimulation patterns to the test.
- Can an inhaled powder stop lung scarring? a safety trial begins
- Avocado at breakfast: a secret weapon for blood sugar and fullness?
- Could a gentle buzz behind the ears tune your heart's rhythm?
- Training Non-Radiology staff to take X-Rays: a feasibility test